Intensity Therapeutics, Inc. (INTS) shares took a beating Friday, falling sharply after the company announced a 1-for-25 reverse stock split designed to boost its per-share trading price and meet Nasdaq's listing requirements. The stock's tumble is particularly notable given that broader markets were enjoying gains, with the S&P 500 up 0.24% and the Nasdaq rising 0.29%.

The reverse split, which shareholders approved back in October 2025, is scheduled to take effect at 4:01 p.m. Eastern Time on February 18, 2026. Trading on a post-split adjusted basis will begin the following day, February 19, 2026. This corporate maneuver will slash the number of outstanding shares from approximately 63.3 million down to about 2.5 million, a move the company hopes will help it regain compliance with Nasdaq's minimum bid price requirement.

Beyond the mechanics of the stock split, Intensity Therapeutics is working to advance its lead product candidate, INT230-6, which is designed for direct intratumoral injection. The company is leveraging its proprietary DfuseRx technology to enhance the effectiveness of cancer therapies, though that longer-term promise isn't doing much to support the stock price today.

The broader market context makes the decline even more striking. The Technology sector is up 1.47% today, yet Intensity Therapeutics is moving in the opposite direction, suggesting that company-specific concerns are overriding any sector tailwinds.

Technical Picture Looks Rough

The technical analysis paints a challenging picture. The stock is currently trading 30.8% below its 20-day simple moving average and 36.1% below its 50-day SMA, signaling significant short-term weakness. Over the past year, shares have plummeted 87.94%, and the stock is positioned much closer to its 52-week lows than highs.

That said, the momentum indicators are sending mixed signals. The RSI sits at 46.41, which is neutral territory, while the MACD is above its signal line, potentially indicating a bullish signal. The combination suggests the stock isn't oversold, but it's not exactly inspiring confidence either.

• Key Resistance: 50 cents
• Key Support: 20 cents

What's Next for Investors

The next major catalyst will arrive with the company's earnings report on March 12, 2026. Analysts are expecting a loss of 5 cents per share, which would actually represent an improvement from the loss of 22 cents per share in the year-ago period. Revenue is estimated at $0.00 million.

INTS Price Action: Intensity Therapeutics shares were down 26.70% at $0.27 at the time of publication Friday. The stock is hovering near its 52-week low of $0.18.